SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)
Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Participants with acute myelogenous leukemia (AML) will be randomized to SCH 727965 or
gemtuzumab ozogamicin. All participants with acute lymphoblastic leukemia (ALL) will receive
SCH 727965. Part 1 of the study will determine the activity of SCH 727965 treatment in
participants with AML and participants with ALL. Part 2 of the study will determine the
activity of SCH 727965 treatment in participants with AML who experienced disease progression
after standard treatment with gemtuzumab ozogamicin during Part 1.